Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2

A longitudinal study conducted in 2021 revealed that the long-term humoral responses against SARS-CoV-2 detected among BNT162b2-vaccinated individuals correlated with individual's ability to produce persistent antigen-specific T-FH and CD4(+) T-cell memory populations. Background Based on the fact that coronavirus disease 2019 (COVID-19) is still spreading despite worldwide vaccine administration, there is an imperative need to understand the underlying mechanisms of vaccine-induced interindividual immune response variations. Methods We compared humoral and cellular immune responses in 127 individuals vaccinated with either BNT162b2, mRNA-1273, or ChAdOx1-nCoV-19 vaccine. Results Both mRNA vaccines induced faster and stronger humoral responses as assessed by high spike- and RBD-specific antibody titers and neutralizing efficacy in comparison to ChAdOx1-nCoV-19 vaccine. At 7 months postvaccination, a decreasing trend in humoral responses was observed, irrespective of the vaccine administered. Correlation analysis between anti-S1 IgG and interferon-gamma (IFN-gamma) production unveiled a heterogeneous immune profile among BNT162b2-vaccinated individuals. Specifically, vaccination in the high-responder group induced sizable populations of polyfunctional memory CD4(+) helper T cells (T(H)1), follicular helper T cells (T-FH), and T cells with features of stemness (T-SCM), along with high neutralizing antibody production that persisted up to 7 months. In contrast, low responders were characterized by significantly lower antibody titers and memory T cells and a considerably lower capacity for interleukin-2 and IFN-gamma production. Conclusions We identified that long-term humoral responses correlate with the individual's ability to produce antigen-specific persistent memory T-cell populations.

Automated summary

A longitudinal study conducted in 2021 found that the long-term humoral responses to SARS-CoV-2 among individuals vaccinated with the BNT162b2 vaccine were correlated with their ability to produce persistent antigen-specific T cell memory populations. mRNA vaccines elicited faster and stronger humoral responses compared to the ChAdOx1-nCoV-19 vaccine. After 7 months of vaccination, there was a decreasing trend in humoral responses. High responders had a diverse immune profile with sizable populations of memory T cells and high neutralizing antibody production, while low responders had lower antibody titers and memory T cells.